Evidence map›Paper›PMID 37982631›Full record

ArticleMicrobiology spectrum2023

Dan Li, Hua Yu, Xiangning Huang, Shanshan Long, Jie Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Carbapenem-resistantFrontiers in cellular and infection microbiology · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dan LiSchool of Medicine, University of Electronic Science and Technology of China , Chengdu, China.
Hua YuDepartment of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu , Sichuan, China.
Xiangning HuangDepartment of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu , Sichuan, China.
Shanshan LongDepartment of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu , Sichuan, China.
Jie ZhangDepartment of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu , Sichuan, China.ORCID 0000-0002-1654-194X
University of Electronic Science and Technology of China · CN

Funding

Health Commission of Sichuan Province () Sichuan-cadres-research 2017-19MOST | National Natural Science Foundation of China (NSFC) 81702064, 82372309Sichuan Science and Technology Program 2022NSFSC1565Sichuan Science and Technology Program 2023JDRC0101
6 · The paper itself

Abstract

importanceTo our knowledge, this is the first study to report the

Indexed as

Carbapenem-Resistant EnterobacteriaceaeKlebsiella InfectionsAnti-Bacterial AgentsAzabicyclo CompoundsAztreonamBacterial Proteinsbeta-LactamasesCarbapenemsCeftazidimeDrug CombinationsHumansImipenemKlebsiella pneumoniaeMicrobial Sensitivity TestsAnti-Bacterial Agentsavibactamavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonamBacterial Proteinsbeta-LactamasesCarbapenemsCeftazidimeDrug CombinationsImipenemrelebactamaztreonam-avibactamcarbapenem-resistantceftazidime-avibactamhypervirulent Klebsiella pneumoniaeimipenem-relebactam

Identifiers

PMID37982631
PMCPMC10848889
OpenAlexW4388825923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.